| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f47654aecfb8f25c7c868b8383be022d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0891db6df402746055dbe722d198b35e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_273cf019144fd08a57391762e5765627
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_caa26644fea5c7e22426bf43347fd67b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_40179495a39da16c96ad427c1a1eb452 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4853
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 |
| filingDate |
2005-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d71f2d50810f420cf78bcb1128846e6c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5bd7c60bb93c72b8ad830d5c33302690
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3990b5d2ddb672194f7bfdcbc0c5753b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25f1c67f27f494e30ca85e78b630a514 |
| publicationDate |
2006-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2006047949-A1 |
| titleOfInvention |
The use of human urinary kallidinogenase for the manufacture of a medicine for the treatment of acute coronary syndromes |
| abstract |
The present invention relates to a novel pharmaceutical use of human urinary kallidinogenase in the manufacture of a medicament for the treatment and/or prevention of acute coronary syndromes. The invention also relates to the pharmaceutical compositions comprising human urinary kallidinogenase as an active ingredient. The human urinary kallidinogenase and the pharmaceutical composition containing the same are effective for the treatment of acute coronary syndromes. The human urinary kallidinogenase composition is generally used in various pharmaceutical formulation forms, preferably in form of dry powder or aqueous solution for injection. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110935015-A |
| priorityDate |
2004-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |